• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

Boston Scientific announces positive data for Eluvia stent

October 7, 2021 By Danielle Kirsh

Boston Scientific copyBoston Scientific this week announced positive data for its Eluvia drug-eluting vascular stent system.

Data presented this week included one-year results from the company’s Eminent trial, which showed superiority of the Eluvia stent compared to self-expanding bare metal stents (BMS) to treat patients with peripheral artery disease (PAD) and superficial femoral artery (SFA) or popliteal artery (PPA) lesions up to 210 mm in length.

The study enrolled 775 patients and had a primary patency rate of 85.4% versus 76.3% with BMS. It also demonstrated a “significantly greater rate” of sustained clinical improvement without reintervention at 83% for patients treated with the Eluvia stent compared to 76.6% for BMS treatment, according to the company. There was no significant difference in major adverse events or all-cause mortality rates between patients treated with the Eluvia stent and patients treated with BMS through one year.

“We are committed to meaningful clinical trials designed to evolve clinical practice, and on the heels of the positive Ranger II SFA data presented yesterday, we are pleased that the Eminent trial establishes the Eluvia stent as the first drug-eluting stent to demonstrate superior primary patency rates compared to bare metal stents in a head-to-head randomized trial,” Michael Jeff, chief medical officer and VP of clinical affairs, technology and innovation, said in a news release. “The breadth of our portfolio, as the only company offering both a drug-coated balloon and a drug-eluting stent for the treatment of patients with PAD, provides physicians with evidence-based and highly-differentiated treatment options.”

Filed Under: Stents Tagged With: Boston Scientific

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS